Janux Therapeutics Inc (JANX) AI Stock Analysis

• Market Cap: $1.65B
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: -97.10%
• EPS Growth: -96.30%
• Country: US
• Employees: 91
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 60,093,933
• 10 Day Avg. Volume: 1,335,173
• 30 Day Avg. Volume: 1,079,897
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $80.00
• Price Target Upside: 179.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $31.00 ▲(8.16% Upside)

Janux Therapeutics Inc shows strong technical momentum, which is the most significant positive factor. However, the company's financial performance is hindered by ongoing losses and negative cash flows, impacting its overall score. The valuation is unattractive due to a negative P/E ratio and no dividend yield, further weighing down the score.

Positive Factors

Revenue Growth

A 30.4% revenue growth indicates strong demand for Janux's innovative therapies, supporting long-term business expansion and market penetration.

Balance Sheet Strength

A robust equity base and minimal leverage provide financial stability, reducing risk and enhancing the company's ability to invest in R&D.

Proprietary Platform Technology

Janux's proprietary technology offers a competitive advantage by developing targeted cancer therapies, potentially leading to successful clinical outcomes and partnerships.

Negative Factors

Profitability Challenges

Ongoing losses and negative margins highlight operational inefficiencies, posing a challenge to achieving sustainable profitability in the near term.

Negative Cash Flow

Negative cash flow from operations indicates reliance on external financing, which can limit financial flexibility and increase risk if not addressed.

High Equity Financing Reliance

Heavy reliance on equity financing can dilute existing shareholders and may not be sustainable if the company fails to achieve profitability.

Janux Therapeutics Inc Business Overview & Revenue Model

Company Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

How the Company Makes Money

Janux Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which often involve upfront payments, milestone payments, and royalties on future sales of products developed from their technologies. Additionally, the company may generate revenue through grants and funding from government entities or non-profit organizations dedicated to cancer research. As they advance their product candidates through clinical trials and towards commercialization, potential licensing agreements with other firms can also serve as a significant source of income.

Janux Therapeutics Inc Financial Statement Overview

Summary

Janux Therapeutics Inc shows strong revenue growth and a robust balance sheet with minimal debt. However, the company faces challenges with profitability and cash generation from operations, as indicated by negative net income and operating cash flows. The reliance on financing to support cash needs is also a concern.

Income Statement

Janux Therapeutics Inc has shown a significant increase in revenue from $8.08 million in 2023 to $10.59 million in 2024, representing a growth rate of approximately 30.4%. However, the company continues to operate at a net loss with a net profit margin of -651.6% for 2024. The gross profit margin remains high at 100%, but negative EBIT and EBITDA margins indicate operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The company maintains a strong equity base with a stockholders' equity of $1.02 billion, indicating solid foundational support. The debt-to-equity ratio is low at 0.02, suggesting minimal leverage which reduces financial risk. However, the equity ratio at 96.3% shows heavy reliance on equity financing. Return on equity is negative, reflecting ongoing losses.

Cash Flow

Operating cash flow is negative, showing the company is not generating cash from its core operations. Nevertheless, there was an improvement in free cash flow from -$52.43 million in 2023 to -$44.17 million in 2024, reflecting a positive growth rate in free cash flow. The financing cash flow remains strong due to significant cash inflows from financing activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-8.07M	10.59M	8.08M	8.61M	3.64M	0.00
Gross Profit	-10.17M	8.53M	6.13M	7.77M	3.52M	-13.00K
EBITDA	-143.86M	-98.85M	-71.02M	-66.25M	-32.82M	-6.57M
Net Income	-105.64M	-68.99M	-58.29M	-63.06M	-32.56M	-5.25M
Balance Sheet
Total Assets	1.03B	1.06B	380.41M	364.01M	379.82M	16.22M
Cash, Cash Equivalents and Short-Term Investments	996.01M	1.03B	344.03M	327.02M	374.96M	7.81M
Total Debt	22.19M	23.02M	24.54M	25.30M	194.00K	0.00
Total Liabilities	41.70M	38.73M	36.06M	43.27M	13.50M	30.86M
Stockholders Equity	990.52M	1.02B	344.35M	320.74M	366.33M	6.99M
Cash Flow
Free Cash Flow	-60.70M	-44.17M	-52.42M	-49.37M	-18.46M	-4.37M
Operating Cash Flow	-59.79M	-43.81M	-50.58M	-42.92M	-16.98M	-4.37M
Investing Cash Flow	-292.23M	-258.02M	-41.19M	58.27M	-340.96M	0.00
Financing Cash Flow	389.81M	713.24M	59.55M	500.00K	386.52M	11.52M

Janux Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 28.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JANX, the sentiment is Positive. The current price of 28.66 is above the 20-day moving average (MA) of 27.15, above the 50-day MA of 25.04, and above the 200-day MA of 27.75, indicating a bullish trend. The MACD of 0.89 indicates Negative momentum. The RSI at 58.59 is Neutral, neither overbought nor oversold. The STOCH value of 44.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JANX.

Janux Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	58 Neutral	$2.10B	-5.29	-62.99%	―	23340.07%	18.06%
JANX	55 Neutral	$1.65B	-15.95	-12.82%	―	-97.10%	-96.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHVS	42 Neutral	$1.39B	―	-63.96%	―	―	-36.92%
EWTX	40 Underperform	$1.83B	―	-27.41%	―	―	-1.46%
BHVN	40 Underperform	$1.48B	―	-295.94%	―	―	16.36%
VERA	39 Underperform	$1.54B	-6.32	-54.83%	―	―	-53.44%

Janux Therapeutics Inc Corporate Events

Janux Therapeutics Advances with Promising Study on JANX008 for Solid Tumor Treatment

Janux Therapeutics, Inc. is conducting a study titled ‘An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of JANX008 in adults with advanced or metastatic carcinoma expressing EGFR. This research is significant as it explores potential treatment options for various challenging cancers.

Janux Therapeutics Advances Prostate Cancer Study with JANX007

Janux Therapeutics, Inc. is conducting a Phase 1 study titled ‘A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC). This research is significant as it explores a potential new treatment for a challenging form of prostate cancer.

Janux Therapeutics Announces Departure of Chief Strategy Officer

Byron Robinson, Ph.D., previously a named executive officer of Janux Therapeutics, Inc., ceased to serve as Chief Strategy Officer and departed from the company effective September 18, 2025. His departure was classified as a termination without ‘Cause’ according to the company’s Change in Control and Severance Benefit Plan.

The most recent analyst rating on (JANX) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on Janux Therapeutics Inc stock, see the JANX Stock Forecast page.

Janux Therapeutics Reports Q2 2025 Financial Results

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel immunotherapies using its proprietary TRACTr, TRACIr, and ARM platforms for cancer and autoimmune diseases.